Cell and gene therapies are advanced therapeutic approaches designed to treat or potentially cure rare genetic disorders by targeting the root cause of disease at the molecular level. Gene therapy focuses on modifying or replacing defective genes within a patient’s cells, while cell therapy involves altering or transplanting cells to restore normal biological function.
These therapies are particularly relevant for conditions such as hemophilia, Duchenne muscular dystrophy, sickle cell disease, and inherited retinal disorders, where traditional treatment options are limited or ineffective. Their ability to deliver long-term or even one-time therapeutic outcomes positions them as transformative solutions in rare disease management.
Advancements in gene-editing tools such as CRISPR/Cas9 and improvements in vector delivery systems have accelerated the development pipeline. Increasing regulatory support and scientific breakthroughs are further strengthening the role of these therapies in reshaping treatment paradigms for rare disorders.
Download the complete TOC and Book a Preview
• Rising unmet medical need for effective treatments in rare genetic diseases
• Increasing adoption of gene-editing technologies such as CRISPR/Cas9
• Potential for curative, long-lasting, or one-time treatment solutions
• Growing investments from pharmaceutical and biotechnology companies
• Advancements in viral vectors and targeted gene delivery mechanisms
• High cost of therapy development and treatment, often reaching millions per patient
• Manufacturing complexities, especially for personalized and small-batch therapies
• Regulatory inconsistencies across regions impacting approval timelines
• Safety concerns including immune responses and unintended genetic effects
• Limited long-term clinical data on efficacy and safety outcomes
• Challenges in patient adherence and post-treatment monitoring requirements
• Ongoing advancements in CRISPR-based gene-editing platforms enabling precise genetic modifications for rare disease treatment
• Increasing number of clinical trials targeting Duchenne muscular dystrophy, hemophilia, and retinal disorders
• Expansion of viral vector technologies such as AAV (adeno-associated virus) for improved gene delivery
• Strategic collaborations between biotech firms and pharmaceutical companies to accelerate commercialization
• Regulatory agencies providing accelerated pathways for rare disease therapies
According to Principal Analyst at BIS Research: “The cell and gene therapies in rare disorders market is entering a pivotal phase, driven by rapid innovation in gene-editing technologies and strong clinical progress. As cost structures improve and regulatory pathways become more streamlined, these therapies are expected to transition from experimental treatments to mainstream solutions. The ability to provide durable or curative outcomes will position this market as a cornerstone of future precision medicine.”
The market is projected to witness strong expansion through 2036, supported by technological advancements and increasing approvals of gene and cell-based therapies.
Key players include F. Hoffmann-La Roche Ltd, Bayer AG, Johnson & Johnson, Pfizer Inc., Sangamo Therapeutics, 4D Molecular Therapeutics, GenSight Biologics, Coave Therapeutics, REGENXBIO, Sarepta Therapeutics, Capricor Therapeutics, Brainstorm Cell Therapeutics, and Abeona Therapeutics.
Gene-editing platforms such as CRISPR/Cas9 and viral vector-based delivery systems dominate the market, while advanced cell therapies are gaining traction for complex rare disorders.
BIS Research provides expert-driven insights, detailed market segmentation, and strategic advisory across healthcare and deep technology sectors.
